Compare Cytokinetics Inc (CYTK) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Thomson Reuters Corp — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Thomson Reuters Corp trades at $103.08 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 5.1× Cytokinetics Inc's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Thomson Reuters Corp for 63 Days on average.
| CYTK | TRI | |
|---|---|---|
Market Cap | $8.62B | $43.89B |
Volume | 2,594,626 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $87.26 | $163.45 |
52-Week Low | $54.76 | $76.55 |
Typical Hold Time | 19 Days | 63 Days |
Enterprise Value | $8.72B | $46.51B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Thomson Reuters (TRI) trades at $101.71, up 2.45% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, positioning for future growth.
The outlook is positive with a consensus price target of $133.25, implying significant upside. Key risks include execution of the AI strategy and cybersecurity concerns. Institutional buying and insider purchases support confidence, but investors should monitor earnings performance and competitive pressures in the legal tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
